ArticleScience immunology2022
An antibody from single human V
Expression of concernOpen access · hybridAbstract read
In one paragraph
Article in Science immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 39 papers.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 58 citations in OpenAlex.
- Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.Viruses · 2026Review
- Broad Neutralizing Activity of Monoclonal Antibodies Against the Omicron Variants Isolated From Patients With Early Severe Acute Respiratory Syndrome Coronavirus-2.Journal of medical virology · 2026Article
- Recurrent SARS-CoV-2 Omicron broadly neutralizing humanized antibodies in different single human VProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Engineering a multivalent antibody nanoparticle to overcome SARS-CoV-2 Omicron immune evasion.PLoS pathogens · 2025Article
- LL-37 Inhibits TMPRSS2-Mediated S2' Site Cleavage and SARS-CoV-2 Infection but Not Omicron Variants.Cell proliferation · 2025Article
- Editorial expression of concern.Science immunology · 2025Article
- Bat sarbecovirus WIV1-CoV bears an adaptive mutation that alters spike dynamics and enhances ACE2 binding.PLoS pathogens · 2025Article
- Organoid-based neutralization assays reveal a distinctive profile of SARS-CoV-2 antibodies and recapitulate the real-world efficacy.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Viral evolution prediction identifies broadly neutralizing antibodies to existing and prospective SARS-CoV-2 variants.Nature microbiology · 2025Article
- Design of SARS-CoV-2 RBD immunogens to focus immune responses toward conserved coronavirus epitopes.Journal of virology · 2025Article
- A Smart Single-Loop-Mediated Isothermal Amplification Facilitates Flexible SNP Probe Design for On-Site Rapid Differentiation of SARS-CoV-2 Omicron Variants.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates.Science translational medicine · 2025Article
- Function and structure of broadly neutralizing antibodies against SARS-CoV-2 Omicron variants isolated from prototype strain infected convalescents.Journal of translational medicine · 2025Article
- Exploring distinct modes of inter-spike cross-linking for enhanced neutralization by SARS-CoV-2 antibodies.Nature communications · 2024Article
- Broad-Spectrum Engineered Multivalent Nanobodies Against SARS-CoV-1/2.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Facilitating and restraining virus infection using cell-attachable soluble viral receptors.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Antibody-mediated control mechanisms of viral infections.Immunological reviews · 2024Review
- Kinetic Landscape of Single Virus-like Particles Highlights the Efficacy of SARS-CoV-2 Internalization.Viruses · 2024Article
- Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants.Viruses · 2024Review
- Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies.iScience · 2024Article
Corrections and comments
- Expression of concern
Authors and funding
30 authors at 3 institutions in 1 country.
Sai LuoHoward Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-7362-5445
Jun ZhangDivision of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-1289-0624
Alex J B KreutzbergerProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-9774-115X
Amanda EatonDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-3064-2947
Robert J EdwardsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-4446-1194
Changbin JingHoward Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0003-0037-2712
Hai-Qiang DaiHoward Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0003-4337-9770
Gregory D SempowskiDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-0391-6594
Kenneth CroninDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-5984-5978
Robert ParksDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-6259-7610
Adam Yongxin YeHoward Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-1542-0740
Katayoun MansouriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0001-6232-7330
Maggie BarrDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Novalia PisheshaProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.
Aimee Chapdelaine WilliamsHoward Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0001-9402-4326
Lucas Vieira FranciscoHoward Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0003-0145-3290
Anand SaminathanProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-9225-5558
Hanqin PengDivision of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-5357-8215
Himanshu BatraHoward Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-0203-0591
Lorenza BellusciDivision of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration (FDA), Silver Spring, MD 20993, USA.ORCID 0000-0001-9945-1706
Surender KhuranaDivision of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration (FDA), Silver Spring, MD 20993, USA.ORCID 0000-0002-0593-7965
S Munir AlamDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-0941-0703
David C MontefioriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Kevin O SaundersDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0001-7399-7954
Ming TianHoward Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0003-4350-3380
Hidde PloeghProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-1090-6071
Tom KirchhausenDepartment of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-0559-893X
Bing ChenDivision of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-8625-1657
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-7643-9023
Frederick W AltHoward Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-0583-1271
Boston Children's Hospital · USDuke University · USCenter for Biologics Evaluation and Research · US
Funding
Nonhuman primate studies for development of a prototype HIV vaccine that induces broadly neutralizing antibodiesUM1AI144371 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2019 to 2025
$190.4MProject 4: Computational panbetaCoV immunogen designP01AI158571 · NIAID · DUKE UNIVERSITY · PI HENDERSON, RORY · 2021 to 2023
$28.0MRegional Biocontainment Laboratory (RBL)UC6AI058607 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, R SANDERS · 2003 to 2005
$16.3MMOLECULAR BASIS OF VIRAL INFECTIVITYT32AI007245 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Aaron Gregory Schmidt · 1985 to 2026
$11.3MStructure-function studies of the membrane-interacting domains of HIV-1 Env spikeR01AI127193 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI CHEN, BING, HARRISON, STEPHEN COPLAN · 2016 to 2025
$8.4MRegional Biocontainment Laboratories Facility and Building System Upgrades SupportG20AI167200 · NIAID · DUKE UNIVERSITY · PI STAATS, HERMAN F · 2021 to 2022
$6.6MVISUALIZATION OF SUBCELLULAR DYNAMICS IN MULTICELLULAR ORGANISMSR35GM130386 · NIGMS · BOSTON CHILDREN'S HOSPITAL · PI TOMAS KIRCHHAUSEN · 2019 to 2026
$4.0M Structure of the full-length spike protein of SARS-CoV-2 in the context of membraneR01AI147884 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI CHEN, BING · 2020 to 2024
$3.4MHoward Hughes Medical InstituteNIAID NIH HHS G20 AI167200NIAID NIH HHS P01 AI158571NIAID NIH HHS R01 AI127193NIAID NIH HHS R01 AI147884NIAID NIH HHS T32 AI007245NIAID NIH HHS UC6 AI058607NIAID NIH HHS UM1 AI144371NIGMS NIH HHS R35 GM130386
Abstract
SARS-CoV-2 Omicron subvariants have generated a worldwide health crisis due to resistance to most approved SARS-CoV-2 neutralizing antibodies and evasion of vaccination-induced antibodies. To manage Omicron subvariants and prepare for new ones, additional means of isolating broad and potent humanized SARS-CoV-2 neutralizing antibodies are desirable. Here, we describe a mouse model in which the primary B cell receptor (BCR) repertoire is generated solely through V(D)J recombination of a human V
Indexed as
COVID-19SARS-CoV-2Angiotensin-Converting Enzyme 2AnimalsAntibodies, NeutralizingAntibodies, ViralEpitopesHumansMembrane FusionMiceReceptors, Antigen, B-CellSpike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralEpitopesReceptors, Antigen, B-CellSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.